I thought that this might have relevance to those of us in the future who may be discontinuing ibrutinib. This article was about another TKI imatinib, but it is worth noting here since it seems to occur in 30% of patients:
Discontinuation of therapy is being explored in patients with chronic myelogenous leukemia (CML) who experience deep molecular responses after treatment with a tyrosine kinase inhibitor (TKI) such as imatinib (Gleevec). However, for the first time, a report indicates that some patients can experience musculoskeletal pain associated with imatinib even after stopping therapy.
Photo: view of sunset from the Tel-Aviv coast a few weeks ago.